Actinogen Medical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATGGF research report →
Price Chart
About the company
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system.
- CEO
- Steven G. Gourlay
- IPO
- 2018
- Employees
- 6
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on ATGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $223.05M
- P/E
- -11.46
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 8.50
- EV/EBITDA
- -6.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -103.42%
- ROIC
- -58.92%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-418,684-107.6%
- Op Income
- $-28,074,204
- Net Income
- $-15,358,298-4.2%
- EPS
- $-0.00+6.1%
- OCF Growth
- -132.1%
- FCF Growth
- -131.0%
- 52W High
- $1.00
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.02
- Beta
- 0.89
- RSI (14)
- 55
- Avg Volume
- 6.84K
No earnings-call transcripts are available for ATGGF yet.
- Free Float
- 82.2%
- Shares Outstanding
- 3.72B
- Float Shares
- 3.06B
Our ATGGF coverage
Recent articles, reports, and earnings notes.
No research on ATGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATGGF report →Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI
proactiveinvestors.com · Oct 1
Actinogen Medical completes final XanaMIA patient visit; November Alzheimer's trial results on track
proactiveinvestors.com · Sep 22
Dow slips, Nasdaq edges lower as August ends in green
proactiveinvestors.com · Aug 31
Nvidia's $12.9bn Hugging Face swoop is really about filling the cloud capacity it has underwritten
proactiveinvestors.com · Aug 28
UBS says bond market relief from falling yields will not offset deeper structural pressures
proactiveinvestors.com · Aug 28
Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO
proactiveinvestors.com · Aug 11
Traders see little chance of Hormuz shipping recovery by end of August
proactiveinvestors.com · Aug 6
Hikma jumps 10% as brokers point to profit beat and undemanding rating
proactiveinvestors.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.